Veru Presents Phase 2 and 3 Enobosarm Data At ADA Scientific Sessions: Well-Tolerated With Comparable Adverse Event Profile To Placebo; Effective In Reducing Fat And Preserving Lean Mass In Older Adults And Cancer Patients
Portfolio Pulse from Benzinga Newsdesk
Veru presented Phase 2 and 3 data for Enobosarm at the ADA Scientific Sessions, showing it is well-tolerated with an adverse event profile comparable to placebo. The drug is effective in reducing fat and preserving lean mass in older adults and cancer patients.
June 24, 2024 | 12:39 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Veru's Enobosarm demonstrated positive Phase 2 and 3 results, being well-tolerated and effective in reducing fat and preserving lean mass in older adults and cancer patients.
The positive results from the Phase 2 and 3 trials of Enobosarm are likely to boost investor confidence in Veru's product pipeline, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100